Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. - Wikidata - wikimedia - TriplyDB

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

http://www.wikidata.org/entity/Q30479628

about

Cord blood graft engineering A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19 Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.Sleeping beauty system to redirect T-cell specificity for human applications.A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Immunotherapy in acute leukemia Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Anti-GD2 Strategy in the Treatment of Neuroblastoma Concise review: umbilical cord blood transplantation: past, present, and future Genetically engineered T cells for the treatment of cancer.Antibody-based immunotherapy in high-risk neuroblastoma.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.Cellular therapies in acute lymphoblastic leukemia Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche.Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Umbilical cord-derived stem cells for tissue therapy: current and future uses.Unrelated umbilical cord blood transplantation and immune reconstitution.Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood trans Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.PET imaging of T cells derived from umbilical cord blood.Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.Double umbilical cord blood transplant: more than a cell dose?Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.Novel cord blood transplant therapies.Umbilical cord blood immunology: relevance to stem cell transplantation.Advances in umbilical cord blood cell therapy: the present and the future.

P2860

Q26822376-5E7169E3-EA6E-4267-BD1D-0EE2B4F06777 Q26849476-93DB1C4D-91F7-472A-BC9C-7D385A2024C3 Q27346600-D060C5FC-556B-4007-BC94-0EA99ED2E329 Q30496580-A605AAD0-75A9-405D-A569-ECF569C5BAAF Q30535187-9444D305-3748-4715-A6ED-E544C687CB43 Q30584839-0ADC15AE-6768-4E60-AF62-F3CA3179DA71 Q33633262-563B2ABE-13F8-44A2-8F5B-877BD14DB560 Q33731552-C5FD319C-C409-4EAD-B69E-6DC5886C5F95 Q33780277-BC5F41FF-593F-4339-A424-85707F290901 Q33819935-42FD193B-E120-4DB2-9855-AB1B28CBF29B Q33852140-E654FC7B-F30A-489E-854F-DD337FCFF775 Q33862876-6B8C387B-8B3B-4099-B493-8875A74A063E Q34122292-531529BD-552E-47CC-8788-C0727E712E9C Q34243887-6FA94665-6C7B-432D-BEBF-3E52506CC3D6 Q34601968-E682A845-FD13-42DD-A242-735296A0C9A3 Q34645898-D800F348-A530-4A59-9274-783CA354C638 Q34725758-93A0C727-373C-459E-A7C8-8B32281F7725 Q34760414-8B062708-B7B6-4C4D-89DB-FC9032BB02A9 Q34987908-D451DF46-0291-475C-B135-4416BF77FBFC Q35962978-82E6E03E-67CF-44A0-9368-CB04F9B33469 Q35967452-751DCA05-6B4A-4A4F-89FC-B5F61B3D2E92 Q36408968-CEC3C317-124B-42C1-8616-B2BD74B43E14 Q36552098-967BDDB4-373C-4F19-A7F4-151B3C96AFCC Q36681962-62BD5391-DA2A-4884-A778-3A6F96C5666C Q36713904-C334F7CE-B4D2-48FD-BC3C-6AE0D379396A Q36801106-EE32ED04-D327-4109-A38C-2FD1DFDB6B9B Q36804511-36B20D7F-26F3-445D-9B94-C6E3C155FBF1 Q36934304-C1F6C680-40DB-4AD3-B909-0D7F1EF3FC71 Q37039243-09F3D1C2-9D30-4E44-A20D-6BD4B37DAFC1 Q37339212-8BE46F59-274F-4F0B-8E6B-FA7A29B4C1BB Q37395931-43777A73-E212-495E-A333-627BC7A136E7 Q37412238-431CE620-9352-4E63-851A-633064B84381 Q37469199-B649CC8C-0BDB-4F73-B222-CC9AEB702A37 Q37536195-85FA57E3-3324-4EA1-B36C-6C4540A6F29E Q37724186-0830D3EE-5DEE-407D-A44C-7119AECA3EAC Q37751873-8DA5895D-5220-4235-9BC0-C72D1F421C26 Q37785538-47353338-4ACE-4830-BE6B-E60933B18A81 Q37800641-D37B9BFB-BDC1-4FDA-BB64-65A384A6D32B Q37963798-C1E2207E-30D1-42F1-8FB7-61154E267139 Q38734758-5F72C0AD-2F6E-47B1-A251-08C112DA36D3

P2860

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

http://www.wikidata.org/entity/Q30479628

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@ast

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@en

type

label

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@ast

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@en

prefLabel

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@ast

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@en

P1433

Q30479628-B09A93E4-345B-46A5-8AE2-4B785FA3BF24

P1476

Q30479628-865C2031-9FAE-49EA-8D63-95539FC266F9

P2093

Q30479628-136C8C50-1AB1-43C4-BB2B-866E9B8E2AD6

Q30479628-3C6AEA40-3406-4A21-9B9A-879324FB230F

Q30479628-4A1C9C67-EA95-48F0-94ED-CDD60CA65564

Q30479628-532D93A0-08A3-4036-95D6-DA468954FCC3

Q30479628-5578B85D-AB5A-4D2F-B6F7-7204FD34D8FA

Q30479628-58B4906A-68E1-44A0-9AAC-FB801CC3EAF4

Q30479628-5C6EE12D-4AE3-4799-B66B-82AF603CD6D2

Q30479628-66F22F4C-71B0-4920-AB53-760C753614BC

Q30479628-95AB1B8B-8487-4DF0-8DB6-4CDED14021B1

Q30479628-A6ACC07A-936C-4B21-81BE-CE6125BE4FE0

P2860

Q30479628-0218F179-21B1-47CF-8A39-84ABE40A6CA4

Q30479628-042388E0-23DD-47D4-B10E-093CA8A8E162

Q30479628-06E87C5D-841D-4A11-A316-5ABD1811E03C

Q30479628-11EBE72D-A8EB-4E0D-92D2-FFDCC78D0FF1

Q30479628-16C0971C-1069-4A79-9254-07F2218995E6

Q30479628-1B3AEF0B-4904-4A0B-AC3B-4B2380BD49B0

Q30479628-1C6875EC-285D-4D5B-B7E2-490B211AE1CB

Q30479628-1DF468DB-2CC4-4CD8-903F-6760A9E88459

Q30479628-22951C03-7C65-4A1A-8EDC-5CE56C36CF72

Q30479628-23D7C0FB-8611-4688-847A-BC94EA77788A

P304

Q30479628-2566D033-A059-4905-AA15-99A79D7A3065

P31

Q30479628-5C206ABA-DAD2-4553-8A02-60787E28E62A

P356

Q30479628-768491EB-9DB6-42EE-B3B1-27C6BCD1B6D4

P407

Q30479628-0F0638B3-627D-41D0-811F-52E59FF30578

P433

Q30479628-BAC400B7-F04D-4536-87DE-18192E3868EE

P478

Q30479628-0E48C464-99C4-4C37-A13F-706B74179052

P577

Q30479628-DC3294E5-3B3E-4467-8BF7-6E6360916E7B

P5875

Q30479628-4535E934-EBC7-4193-B1CF-ED1A3F965F49

P698

Q30479628-AE339494-C6C7-4509-B36F-ACF5A445407F

P921

Q30479628-202210DA-2256-42B5-B7D5-6812B08A335B

P932

Q30479628-5D08B68E-AF9B-46EB-ABE6-FBF0BA527934

P356

BLOOD-2005-09-3904

P1433

P1476

Differentiation of naive cord- ...... tation adoptive immunotherapy.

@en

P2093

Daniel Kim

http://www.w3.org/2001/XMLSchema#string

David Smith

http://www.w3.org/2001/XMLSchema#string

George McNamara

http://www.w3.org/2001/XMLSchema#string

Jennifer Bennitt

http://www.w3.org/2001/XMLSchema#string

Joseph Rosenthal

http://www.w3.org/2001/XMLSchema#string

Laurence J N Cooper

http://www.w3.org/2001/XMLSchema#string

Lisa Marie Serrano

http://www.w3.org/2001/XMLSchema#string

Michael C Jensen

http://www.w3.org/2001/XMLSchema#string

Simon Olivares

http://www.w3.org/2001/XMLSchema#string

Stephen J Forman

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma

Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia

Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production

Immunobiologic differences between normal and leukemic human B-cell precursors.

Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes

Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal.

Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines.

Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells.

P304

2643-2652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-09-3904

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7416835

http://www.w3.org/2001/XMLSchema#string

P698

16352804

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895371

http://www.w3.org/2001/XMLSchema#string